News

The program will continue to focus on utilizing Ionian’s proprietary isothermal nucleic acid amplification technology, the NEAR Assay, to develop a platform for various global health diseases that

CEL-SCI Corporation (CEL-SCI) has initiated clinical study for hospitalised H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins). The study is being led by Principal

Genzyme has reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB

Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and Ube Industries. Effient helps keep blood platelets from clumping together and developing

The company said that the application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation. The company claims that the essence of

Affiris will focus its Alzheimer’s vaccine program on one product candidate at an unexpectedly early stage of development that the vaccine candidate AD02 is planned to enter into

Covance has entered into a biomarker alliance and services agreement with Rules-Based Medicine (RBM). As per the terms of the agreement, Covance is expected to use RBM as

PPD has signed an agreement to acquire BioDuro, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand

NanoString Technologies (NanoString) is collaborating with the Broad Institute of MIT and Harvard, to investigate molecular networks involved in immune response and other important biological processes. Reportedly, the